everyone. company. Peter, a of discussing welcome the far. so you, important and for during our morning, for will call And where had good and conference earnings to this be progress recent fiscal 'XX quarter Biostage for Biostage, has Thank the quarterly we developments number
So let me review those.
tract. patent to applications a U.S. or airway issuance First, Xth the patent we've our the strengthened patent in the our protects with patent the intellectual gastrointestinal new currently protected for United use in -- of States or property intellectual the the portfolio esophagus -- our is bronchus Xth portfolio addition in technology that that
for wrongdoing lawsuit was quarter, or first Biostage. Second, of been against following any This lawsuit a of years. outstanding five for settled the that liability almost admission end had settled without we our us
groundwork on and shares the for our continued placement $X.X we end the closed, the able to be to to QX, million. us FDA capital, In we recently company to of quarter, first a NASDAQ clinical post approximately also to the to lay raise in approved in further trial. relist prepare of Third, patient private the to for apply treat
worth to I some milestone got point. this it's recapping achievements of us have that think the
in first This the human up implant into surgeons XX of Biostage have of respected the in use.” performed number Dennis our first esophagus by “Revolutionary Wigle, by performed an is a one Chair most considerable clinical in biotech experience as concluded enormous This clinical Surgery trials. company research described going clinic, Biostage we a regeneration esophageal Other That cancer ever at of of the hospitals. have that the backed was an That First, the paper “A is of more human Thoracic product patient. Mayo for world's the pigs. breakthrough.” “Would Dr. than or pigs implant esophageal
of Some years. two almost those for pigs out were taken
these four clinical This States. that the technology, a to a strategic FDA pharmaceuticals investors they're Hence, study the implants $XX in One in placement. regeneration and in X the Phase And trial typical the patent study was we similar potential, in QX None these raised esophagus, efficacy protects was in measures Biostage volunteers. to safety fund. as X -- population. personnel our The excludes patient investors. in from this the more and is trial up hospitals it investors in maximum bronchus. application in those safety long-term patients the in Most United a XX Biostage’s healthy both approved in know that placement. issued hedge recent actual last was X its of miniature that its was to of And for $X private million got a recent has not like of trial but the private and than of is private functional just had in the a years a esophagus. pig showed the individuals actually seen treated million bronchus Phase this pigs over in bronchus. on The the adult the
One of when in And November I'm in options. me. in I required from last joined I these back is $XXX,XXX paid year. entirely investors stock invested legally wage, apart the Biostage minimum
not also As million cash on of the I’m I week. round. $X.X in My I've month financing employment private mentioned this a every invested earlier, also Hence flow company. last closed placement the is round of a Biostage. we in recent investing drain
through in stock our part also of employees options. All are compensated
United China, retrievable one new the nature the We have which scaffold, the in patents no issued the X in the These the in bioreactor, body. bronchus. cover and of scaffold on leaves States and implant the permanent X which includes the
the We product. years the Orphan to in addition exclusivity also have Designations, Drug X of patents approval can provide of United which an X as States from date of the the
and has in capital NASDAQ, to Peter quarter the review financials one. its years to last goals Peter? I'll the additional on the short-term raise begin Biostage trial. in clinical turn to and to now lot back accomplished relist call are a few of So current and QX. to And the
